Ernexa Therapeutics Inc. Common Stock
ERNAStock
$7.12−85.98%52W
Market Cap$8.42M
P/E—
Div yield—
Beta2.51
Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-87.75%
Price vs S&P 500 (4W)9.73%
VGM Score33.48
Market Capitalization$8.42M
Analyst Recommendations
Feb 2023
Mar 2023
Jun 2026
Jul 2026
2.17
2.17
4.14
4.14
Industry Peers — Pharmaceuticals(563)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ERNAErnexa Therapeutics Inc. Common Stock | C | F | C | $7.12 |
| LLYEli Lilly & Co. | D | B | B | $1169.17 |
| JNJJohnson & Johnson | D | C | B | $249.97 |
| ABBVABBVIE INC. | D | C | B | $254.39 |
| MRKMerck & Co., Inc. | C | C | B | $127.63 |
| NVSNovartis AG | C | C | C | $152.73 |
| NVONovo-Nordisk A/S | C | B | C | $51.48 |
| AZNAstraZeneca PLC | C | B | C | $169.29 |
| ABTAbbott Laboratories | C | C | D | $98.83 |
| PFEPfizer Inc. | B | C | C | $25.14 |
| VRTXVertex Pharmaceuticals Inc | D | C | C | $486.03 |
About
Ernexa Therapeutics is a biotechnology company developing cell-engineered medicines for cancer and autoimmune diseases. The company's proprietary platform converts induced pluripotent stem cells (iPSCs) into induced mesenchymal stem cells (iMSCs) to create off-the-shelf cellular therapies, eliminating the need for patient-specific cell harvesting. This approach offers potential advantages in manufacturing scalability and cost-efficiency.